Getting Safe Returns With This Health Care ETF (IYH, JNJ)
Since starting my True Wealth newsletter in 2001, I’ve avoided buying big U.S. stocks. I’ve avoided big-name stocks because I thought they were too expensive. But now, for the first time in my career, I’m finding value in some big U.S. stocks… particularly in one sector.
Look, stocks today (as measured by the big indexes) are currently cheaper than they were 11 years ago, back in 1999. The important thing is this: While the share prices are lower, many companies have grown dramatically…
Consider the case of Johnson & Johnson (NYSE:JNJ)… Its share price is in the $50s today, like it was at its highs in 1999. But since then, the business has grown dramatically. Now, you get a whole lot more business for your investment buck.
Warren Buffett – the world’s most successful investor – likes to measure the growth in his business by its growth in book value. By that measure, Johnson & Johnson (NYSE:JNJ) is 70% cheaper today than it was in 1999 because of its growth. Back then, J&J traded for 10 times book value. It trades at three times book value today.
J&J (NYSE:JNJ) has rarely been this cheap… And history tells us we really want to own it when it gets cheap!
J&J dipped below four times book value in early 1994… The share price soared 150% within two years. You have to go back a quarter-century to find it as cheap as it is today. And of course, the stock soared after that as well: Shares doubled in less than two years and tripled in just over three years.
It’s also cheap when you look at earnings. J&J is trading at 12 times earnings right now. Shares have only been this cheap a couple times in history. In all instances, you could have made a heck of a lot of money…
- J&J fell to 11.9 times earnings in March 1980. The stock doubled in less than three years.
- In June ’84, it traded down to 10.9 times earnings. The stock nearly tripled over the next three years.
- Its next big valuation low was April 1994, at a price to earnings of 13.8. The stock tripled in three years.
It seems like investors have given up on drug companies like J&J. Whether it’s worries about patent expiration’s, dry drug “pipelines,” lawsuits… or just simply boredom after a decade of no return, shareholders have thrown in the towel.
But J&J isn’t going away. I don’t know about at your house, but around my house we are big J&J customers for life – without even realizing it…
We use Listerine. We have for decades. We aren’t changing. We use Band-Aids. We have for decades. And we aren’t changing. We use Neosporin… The list goes on, longer than you can
imagine. These are all Johnson & Johnson brands.
And then there are the drugs, including Tylenol, Motrin, Sudafed, Benadryl, and more. J&J has probably infiltrated our house more than any other company in America. These J&J brands are insulated from economic downturns. We will continue to use these products at home… indefinitely.
And these are just a few examples of brands you recognize from J&J. The company does a lot more than Band-Aids and Tylenol. Importantly, it holds the No. 1 or No. 2 rank in 70% of its products.
Despite all of this… the stock is dirt-cheap. I was talking about this with my colleague Frank Curzio, who writes the super-exclusive Phase 1 Investor advisory. He said, “I can’t think of one risk that’s not already priced into these stocks… and at some price, everything is a buy.”
I think “some price” is today’s price…
Keep in mind, Johnson & Johnson is a no-debt business. (With $18 billion in cash, it has more cash than debt.) It has an incredible collection of brands, which should insulate it from economic downturns. It has one of the best drug pipelines in the industry: It’s developing drugs for pain, arthritis, and heart disease. Finally, the company knows its stock is cheap… It has bought back $9 billion worth of its own stock since 2007, and will likely buy back $1 billion more over the rest of this year.
Most big pharmaceutical companies are at record cheap values – by far. Many are significantly cheaper than Johnson & Johnson. History shows when these stocks get this cheap, triple-digit gains follow.
In True Wealth, I look for sectors that are cheap, hated/ignored, and just starting an uptrend.
Big drug companies are record cheap, investors have given up on them, and we might be seeing a glimmer of an uptrend.
A safe, simple way to play the big drug companies is through the iShares U.S. Health Care ETF (NYSE:IYH). Its largest holding, incidentally, is Johnson & Johnson.
I’m almost never interested in Big Pharma… But I’m buying now. It’s just too cheap to ignore.
P.S. In the latest issue of True Wealth, I recommended a unique way to get into Big Pharma. It’s not a typical stock or a mutual fund… but I believe we have the potential for gains of up to 300% over the next three years… profiting from the exact Big Pharma companies we want to own. Click here to sign up for True Wealth.
We have put together some more details on the iShares U.S. Health Care ETF (NYSE:IYH) below for you to take a look at.
iShares U.S. Health Care ETF (NYSE:IYH)
The investment seeks investment results that tracks Dow Jones U.S. Health Care Index. The fund generally invests at least 90% of assets in securities of the underlying index and depositary receipts representing securities of the underlying index. It may invest the remainder of assets in securities not included in the underlying index but which BGFA believes will help the fund track underlying index, and in futures contracts, options on futures contracts, options and swaps as well as cash and cash equivalents, including shares of money market funds advised by BGFA. The fund is nondiversified.
|TOP 10 HOLDINGS ( 55.19% OF TOTAL ASSETS)|